Table 3.
Difference in E2 production per follicle associated with patient characteristics (Adjusted Analysis)
| Patient Characteristic | Difference in E2 production per follicle (95% CI) | P-value |
|---|---|---|
|
| ||
| FSH Dose | ||
| Low Dose | (reference) | |
| Medium Dose | 1.2 (−2.0, 4.4) | 0.47 |
| High Dose | 5.2 (2.0, 8.5) | <0.01 |
|
| ||
| Diagnosis | ||
| Ovulatory Controls | (reference) | |
| Polycystic Ovary Syndrome | −4.9 (−9.7, −0.3) | 0.04 |
|
| ||
| Age (per year) | 0.0 (−0.2, 0.3) | 0.85 |
|
| ||
| Body Mass Index (per point) | −0.1 (−0.4, 0.2) | 0.63 |
|
| ||
| Total Testosteronea (per ng/mL) | 0.2 (0.04, 0.38) | 0.02 |
|
| ||
| Antimüllerian Hormonea (per ng/mL) | −0.4 (−0.6, −0.1) | <0.01 |
Pooled, adjusted analysis (n=30) of the difference in Peak E2 production per follicle (pg/mL/follicle) associated with patient variables as determined by linear mixed effects modeling with random intercept structure while adjusting for age, body mass index, total testosterone concentration, and antimüllerian hormone level.
a
Baseline levels. Bold text indicates a statistically significant difference with a p-value < 0.